The conflicting PTEN-deficient tumor cell data in these studies may be due to the inherently complex genomic and biochemical landscape of tumors, which can accumulate multiple genetic lesions (in addition to PTEN loss), and heterogeneity, but also multiple genetic vulnerabilities, pleotropic roles, and microenvironmental changes throughout tumorigenesis, anti-tumor therapy, and recurrence [75,82]. Here, PTEN is linked to neoplasm.